ABBOTT INTRODUCES LIBRE SENSE GLUCOSE SPORT BIOSENSOR IN EUROPE, WORLD'S FIRST GLUCOSE BIOSENSOR DESIGNED FOR ATHLETES

[Northerner]

Press Release:
- Abbott's Libre Sense Glucose Sport Biosensor, with CE Mark, is built upon the company's world-leading continuous glucose monitoring technology

- Abbott is collaborating with sports performance technology company Supersapiens to advance this first-of-its-kind product

- As part of an observational trial, two cycling teams leading into the world's largest annual sporting event, the Tour de France, trained with Abbott's Libre Sense biosensor to track the correlation between glucose levels and their athletic performance

Abbott (NYSE: ABT) is introducing the world's first glucose sport biosensor,i Libre Sense Glucose Sport Biosensor, which is designed for athletes to continuously measure glucose to better understand the correlation between their glucose levels and their athletic performance. The Libre Sense biosensor is based on Abbott's world-leadingii FreeStyle Libre continuous glucose monitoring technology, which was originally developed for people living with diabetes. Based on that technology, this is the first personal-use product that allows for use beyond diabetes.

Abbott's Libre Sense Glucose Sport Biosensor, with CE Mark (Conformité Européenne), is a consumer over-the-counter product that provides glucose monitoring via a mobile appiii to athletes (ages 16 years and older) performing sports such as cycling, running, and swimming, to understand the efficacy of their nutrition choices on training and competition. Tracking and understanding glucose levels enable athletes to fuel appropriately through nutrition to help avoid fatigue from low glucose and to know when to replenish during training and competition to maintain peak performance.

"FreeStyle Libre changed the way millions of people manage their diabetes to get and stay healthier, and now with Libre Sense we're bringing that same proven technology to empower athletes to help them reach their athletic performance goals," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "This is just the beginning – our breakthrough sensing technology has the potential to go beyond glucose and provide a lens into what's happening in the human body that could provide meaningful insights into other conditions, treatments, and ultimately improve health."

Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes

Abbott (NYSE: ABT) is introducing the world's first glucose sport biosensor,i Libre Sense Glucose Sport Biosensor, which is designed for athletes to continuously measure glucose to better...

abbott.mediaroom.com

(I was going to post in News section, but thought more might see it here - Mods move if you wish 🙂 )

 

[Bruce Stephens]

That's interesting. I saw an advert on twitter for something that's obviously (and transparently once I looked hard enough) FreeStyle Libre, but for the general public. I forget the branding.

(That suggests they're trying to sell the thing to non-diabetics (and people who aren't making TV documentaries about diets). I can see why it would seem worth doing; sports feels more likely to work than what I saw on twitter, but maybe the less targeted market is big enough in the US (presuming that's where it was aimed).)